Analyst Price Targets — ZVRA
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| March 10, 2026 10:40 am | Eddie Hickman | Guggenheim | $23.00 | $11.03 | StreetInsider | Zevra Therapeutics, Inc. (ZVRA) PT Raised to $23 at Guggenheim |
| December 30, 2025 11:38 am | Brandon Folkes | H.C. Wainwright | $26.00 | $8.82 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on Zevra Therapeutics, Inc. (ZVRA) |
| November 6, 2025 2:04 pm | Kristen Kluska | Cantor Fitzgerald | $24.00 | $9.29 | TheFly | Zevra Therapeutics price target lowered to $24 from $29 at Cantor Fitzgerald |
| November 6, 2025 1:48 pm | — | Canaccord Genuity | $24.00 | $8.95 | TheFly | Zevra Therapeutics price target lowered to $24 from $25 at Canaccord |
| March 13, 2025 12:25 pm | — | Guggenheim | $22.00 | $7.94 | TheFly | Zevra Therapeutics price target raised to $22 from $20 at Guggenheim |
| March 12, 2025 9:42 am | — | JMP Securities | $18.00 | $7.92 | TheFly | Zevra Therapeutics price target raised to $18 from $17 at Citizens JMP |
| February 4, 2025 2:05 pm | Zevra Therapeutics to $ | Guggenheim | $21.00 | $8.13 | TheFly | Zevra Therapeutics price target raised to $21 from $20 at Guggenheim |
| September 24, 2024 8:15 am | Jonathan Aschoff | Roth Capital | $21.00 | $7.58 | TheFly | Zevra Therapeutics price target raised to $21 from $19 at Roth MKM |
| September 24, 2024 7:56 am | Jason McCarthy | Maxim Group | $25.00 | $7.58 | StreetInsider | Zevra Therapeutics, Inc. (ZVRA) PT Raised to $25 at Maxim Group |
| September 24, 2024 2:37 am | Jason Butler | JMP Securities | $17.00 | $7.58 | StreetInsider | JMP Securities Starts Zevra Therapeutics, Inc. (ZVRA) at Market Outperform |
Latest News for ZVRA
Zevra Therapeutics, Inc. (NASDAQ: ZVRA - Get Free Report) has received an average recommendation of "Moderate Buy" from the nine analysts that are currently covering the firm, MarketBeat Ratings reports. Two research analysts have rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average 12 month price
BOSTON, March 20, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced that the Company has granted as of March 18, 2026 an equity inducement award to Justin Renz, the Company's new Chief Financial Officer pursuant to the Company's 2023 Employment Inducement Award Plan…
BOSTON, March 16, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced an agreement under which Commave Therapeutics SA (Commave) will purchase Zevra's serdexmethylphenidate (SDX) portfolio, including AZSTARYS® and KP1077, for $50 million. "We are pleased to have…
It also posted 44% net revenue growth for the period. Both headline figures crushed the consensus analyst estimates.
Zevra Therapeutics delivered robust FY25 results, with 350% revenue growth to $106.5M and a GAAP EPS of $1.40, driven by Miplyffa's commercial launch. Miplyffa's rapid adoption in the ultra-rare NPC market, supported by expanded payer coverage and diagnostic initiatives, underpins ZVRA's strong commercial momentum. ZVRA trades at discounted valuation multiples (16.9x forward P/E, 10.7x EV/EBIT), reflecting market…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ZVRA.
U.S. House Trading
No House trades found for ZVRA.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.